DA
NKTR icon

Duality Advisers’s Nektar Therapeutics NKTR Stock Holding History

Duality Advisers’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-22,825
Closed -$1.84M – 777
2022
Q1 		$1.84M Buy
+22,825
New +$3.38M 0.2% 175
2020
Q3 		– Sell
-8,308
Closed -$2.89M – 632
2020
Q2 		$2.89M Buy
+8,308
New +$2.59M 0.26% 106
2020
Q1 		– Sell
-18,285
Closed -$5.92M – 220
2019
Q4 		$5.92M Buy
+18,285
New +$5.3M 0.35% 100

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Duality Advisers's NKTR Position: Q2 2022 in Review

Duality Advisers sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 22,825 shares — an estimated $1.84M sold.

Duality Advisers first reported a position in NKTR in Q4 2019 and held it in 3 quarters. The position peaked at $5.92M in Q4 2019. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

  • Duality Advisers reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Duality Advisers sold 22,825 Nektar Therapeutics shares in Q2 2022, an estimated $1.84M.
  • Duality Advisers first reported a position in Nektar Therapeutics in Q4 2019 and held it in 3 quarters.
  • Duality Advisers's Nektar Therapeutics position peaked at $5.92M in Q4 2019.
  • 227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on Duality Advisers's 13F filing for Q2 2022, filed 8 Aug 2022.